Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Open accessThe DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The two phenomena of extravasation and later diffusion and convection of the colloid in the extracellular matrix both result in enhanced permeation and retention of the nanoparticles [32].](https://figures.cochat.ai/paper-figures/887ab73c266443efbb3420cd636da176/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-1.jpg)
![Figure 2 Common strategies utilizing the EPR effect [109].](https://figures.cochat.ai/paper-figures/89ba4512a64543b1a593fb62b3bf1725/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In clinical settings, one of the main challenges for the delivery of macromolecules and nanomedicine to the cancer site is due to the heterogeneity of the EPR effect in solid tumors [20].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated that only 0.1 to 0.2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 1×
“The rapid tumor growth and improper development of blood vessels in murine tumors result in a much leakier vasculature as compared to human tumors that can lead to misinterpretation of the EPR effect [78].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“The liposomal doxorubicin extravasated and accumulated intact in tumors with a leaky vasculature [79].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“The physicochemical properties of any external material for therapeutic or diagnostic purposes are important in drug delivery as they impact the way the host defense mechanisms clear them from the systemic circulation [57,58].”
BackgroundLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180 · cited 3×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039 · cited 1×
“These nanoparticles with a size below 50 nm are mostly used for the detection of brain tumors [140].”
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864 · cited 1×
“and spleen, but large enough to avoid kidney clearance [7,8].”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Research works printed but not linked: 1
- Dellian, 2000, Vascular permeability in a human tumour xenograft: Molecular charge dependence, Br. J. Cancer, 82, 1513
Cited by
Items 201–300 of 657
Tefas, L. R., Toma, I., Sesărman, A., Banciu, M., Jurj, A. M., Berindan‐Neagoe, I., Rus, L., Stiufiuc, R. I., & Tomuță, I. (2022) · Journal of Liposome Research · doi:10.1080/08982104.2022.2153139 · Cited by 17
“It has been reported that spherical particles with sizes ranging between 50 nm and 200 nm exhibit a long circulation time, reduced clearance and enhanced accumulation in tumors (Subhan et al. 2021, Teixeira et al. 2022).”
BackgroundMilewska, S., Siemiaszko, G., Wilczewska, A. Z., Misztalewska‐Turkowicz, I., Markiewicz, K. H., Szymczuk, D., Sawicka, D., Car, H., Łaźny, R., & Niemirowicz-Laskowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021364 · Cited by 18
“In clinical practice, using the EPR effect is the main idea in the passive targeting of solid tumors in cancer nanotherapy [11,12].”
BackgroundDesign of Rapamycin and Resveratrol Coloaded Liposomal Formulation for Breast Cancer Therapy
dos Reis, L. R., Luiz, M. T., Sábio, R. M., Marena, G. D., Filippo, L. D. D., Duarte, J. L., Fernandes, L. D. S., Araújo, V. H. S., Silva, V. A. O., & Chorilli, M. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0227 · Cited by 17
Villa, A. M., Mitri, Z. D., Vincenti, S., Crippa, E., Castiglioni, L., Gelosa, P., Rebecchi, M., Tosi, D., Brunialti, E., Oevermann, A., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116201 · Cited by 18
“…for tumor regions due to the prevailing enhanced permeability and retention (EPR) effect, characteristic of tumor-associated endothelial permeability, which leads to the passive accumulation of contrast agents – but also of therapeutic drugs and other molecules - in the tumor microenvironment [4].”
Fu, W. Y., CHIU, Y., Huang, S.-C., Huang, W., Hsu, F.-T., Lee, H. Y., Wang, T., & Keng, P. Y. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00298 · Cited by 17
Targeted drug delivery in cancer using nanomaterials: advances and challenges
Sharma, T., Gorivale, S., & Bhandari, P. (2024) · Journal of Nanoparticle Research · doi:10.1007/s11051-024-06023-1 · Cited by 18
“The manifestation of the EPR effect is contingent upon the inherent biological characteristics of the tumour [89], specifically: (1) the extent of angio-and lymph-genesis, (2) the extent of perivascular tumour expansion and the density of the stromal reaction, and (3) the intratumoural pressure…”
Nano-oncology revisited: Insights on precise therapeutic advances and challenges in tumor
Teng, L., Bi, Y., Xing, X., & Yao, G. (2025) · Fundamental Research · doi:10.1016/j.fmre.2025.03.024 · Cited by 17
“In contrast, molecules smaller than 4 nm are rapidly reabsorbed and returned to the blood-stream [ 68 ].”
Targeted therapies against breast cancer: Clinical perspectives, obstacles and new opportunities
Nagpal, D., Verma, R., Mittal, V., Jeandet, P., & Kaushik, D. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105049 · Cited by 22
Gan, L., Lin, X., Zhong, Z., Zheng, Y., Chen, X., Chen, J., Xiao, Y., Liu, Y., Pan, X., Wu, C., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.043 · Cited by 17
The portrayal of macrophages as tools and targets: A paradigm shift in cancer management
Jain, N., Srinivasarao, D. A., Famta, P., Shah, S., Vambhurkar, G. B., Shahrukh, S., Singh, S. B., & Srivastava, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121399 · Cited by 17
Masoudi, M., Taghdisi, S. M., Hashemitabar, G., & Abnous, K. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01495-5 · Cited by 16
“Due to the enhanced permeability and retention (EPR) effect which is caused by leaky vasculature and defective lymphatic drainage around tumor, nanodelivery systems tend to enter and accumulate in tumors more than other organs [25].”
Unlocking nature's arsenal: Nanotechnology for targeted delivery of venom toxins in cancer therapy
Chary, P. S., Shaikh, S., Rajana, N., Bhavana, V., & Mehra, N. K. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.213903 · Cited by 17
Rajan, S. S., Chandran, R., & Abrahamse, H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s486014 · Cited by 17
“80 When encapsulated within nanocarriers, hypocrellin can exploit this passive targeting mechanism, allowing for its selective delivery to cancerous tissues while minimizing exposure to healthy cells.”
BackgroundMunyayi, T. A., & Crous, A. (2025) · Cancers · doi:10.3390/cancers17020198 · Cited by 19
“EPR efficiency measures the effectiveness of this phenomenon in delivering therapeutic agents to tumor sites, with higher efficiency indicating better accumulation and retention of the drug in the tumor [15].”
Gharehbaba, A. M., Soltanmohammadi, F., Vandghanooni, S., Eskandani, M., & Adibkia, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118045 · Cited by 18
A Review of Gold Nanoparticles: Synthesis Methods and Biomedical Applications
Mehdi, J., Ansari, V. A., & Singh, A. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00421-2 · Cited by 21
Sorasitthiyanukarn, F. N., Muangnoi, C., Gomez, C. B., Suksamrarn, A., Rojsitthisak, P., & Rojsitthisak, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020472 · Cited by 17
“The NPs with a particle size range of approximately 40 to 400 nm are appropriate to ensure a long circulation time and an enhanced drug accumulation in the cancer cells with reduced renal clearance [37].”
Background“Nano-Paclitaxel” Unlocking Potential and Redefining Cancer Chemotherapy
Muley, A., Navale, A., Gupta, R., & Tekade, R. K. (2025) · ACS Omega · doi:10.1021/acsomega.5c02916 · Cited by 15
Lee, H. W., Seo, H. S., Yeom, S.-Y., Kim, S.-N., Kim, C. R., Park, D.-H., Park, W., Choy, Y. B., Park, C. G., & Seo, S. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012634 · Cited by 15
Chen, L., Fujisawa, N., Takanohashi, M., & Ebara, M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1046147 · Cited by 15
“A significant benefit of this effect is that it allows selective drug delivery to cancerous tumors (Maeda and Islam, 2020; Subhan et al., 2021).”
BackgroundPrasad, A., Sekar, R. P., A, M. R. C., Sudhamani, S. D., Das, A., Jayakrishnan, A., & Ngashangva, L. (2024) · Biomedical Materials · doi:10.1088/1748-605x/ad7f3a · Cited by 15
Basingab, F. S., Alshahrani, O. A., AlAnsari, I., Almarghalani, N. A., Alshelali, N. H., Alsaiary, A. H., Alharbi, N. M., & Zaher, K. A. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s501448 · Cited by 23
“114 In contrast, active targeting involves the modification of therapeutic agents with specific ligands that bind to receptors or antigens overexpressed on the surface of cancer cells.”
Design principles of bioinspired interfaces for biomedical applications in therapeutics and imaging
Shih, C.-P., Tang, X., Kuo, C. W., Chueh, D., & Chen, P. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.990171 · Cited by 18
“solid tumors, which normally has less efficiency (Subhan et al., 2021).”
BackgroundMultimodal imaging distribution assessment of a liposomal antibiotic in an infectious disease model
Cheng, S., Groseclose, M. R., Mininger, C., Bergström, M., Zhang, L., Lenhard, S. C., Skedzielewski, T., Kelley, Z. D., Comroe, D., Hong, H., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.061 · Cited by 15
Kaurenoic acid nanocarriers regulates cytokine production and inhibit breast cancer cell migration
Ferreira, K. C. B., Valle, A. B. C. D. S., Gualberto, A. C. M., Aleixo, D. T., Silva, L. M., Santos, M. M., Costa, D. D. S., Oliveira, L. L., Gameiro, J., Tavares, G. D., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.048 · Cited by 15
Engineered upconversion nanoparticles for breast cancer theranostics
Wang, S., Zhang, L., Wang, M., Yin, X.-M., Dong, X., Wu, X., Li, W., Xu, W., & Mao, X. (2025) · Theranostics · doi:10.7150/thno.116153 · Cited by 15
Sakkal, M., Abdelmoteleb, R. W. A., Ali, A., Jardan, Y. A. B., Löbenberg, R., & Sarfraz, M. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00046-y · Cited by 14
“Additionally, the lymphatic drainage in tumors is often impaired, leading to the retention of the nanoparticles within the tumor site (Subhan et al. 2021).”
Xiao, B., Ackun‐Farmmer, M. A., Adjei‐Sowah, E., Liu, Y., Chandrasiri, I., & Benoit, D. S. W. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01022 · Cited by 14
Archana, M. G., Anusree, K. S., Unnikrishnan, B. S., Reshma, P. L., Syama, H. P., Sreekutty, J., Joseph, M. M., & Sreelekha, T. T. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c02532 · Cited by 14
Functionalised Ligand-Based Nanomaterial Drug Targeting Approaches for Colorectal Cancer Therapy
Dixit, A. A., Mandlik, D. S., & Mandlik, S. K. (2024) · Recent Advances in Drug Delivery and Formulation · doi:10.2174/0126673878301004240703073107 · Cited by 14
Recent advances in targeted drug delivery systems for multiple myeloma
Pant, A., Laliwala, A., Holstein, S. A., & Mohs, A. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.003 · Cited by 16
Jester, M. T., Haley, R. M., Billingsley, M. M., Figueroa‐Espada, C. G., Joseph, R. A., Han, X., & Mitchell, M. J. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101457 · Cited by 17
“7,8 Direct injection of anticancer drugs into the tumor site could alleviate many of these issues, allowing for high local concentration of anti-cancer therapeutics and limited off-site binding and effects.”
Polymeric Micelles in Targeted Breast Cancer Therapy:Recent Advances and Future Trends
Soni, A., & Jaiswal, V. P. (2025) · Nano Biomedicine and Engineering · doi:10.26599/nbe.2025.9290122 · Cited by 14
Sharif, N., Murtaza, I., Shahnaz, G., Saeed, A., Ishtiaq, A., Tabassum, S., Rahdar, A., Fathi‐karkan, S., & Pandey, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144656 · Cited by 17
Raza, M. A., Khatoon, N., Parveen, R., Nirisha, V., Thakur, Y., Thakur, Y., Lata, K. A., Shifana, A. S., Disouza, J., Saoji, S. D., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145145 · Cited by 14
Gahtani, R. M., Alqahtani, A., Alqahtani, T., Asiri, S. A., Mohamed, J. M. M., Prabhu, S. V., & Muluneh, E. Y. (2023) · Bioinorganic Chemistry and Applications · doi:10.1155/2023/2334675 · Cited by 14
RetractedGuo, X.-M., Lin, J., Pan, L., He, K., Huang, Z., Chen, J., Lin, C., Zeng, B., Luo, S., & Wang, M. (2023) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2023.2268137 · Cited by 14
“Due to the enhanced permeability and retention effect, nanoparticles within the range of 40–400 nm are more likely to accumulate in tumour tissues, thereby improving the targeted delivery of therapeutic drugs [32].”
BackgroundTargeting the oral tumor microenvironment by nanoparticles: A review of progresses
Zhang, H., Zhou, F., Yang, Q., & Huang, M. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105248 · Cited by 14
Askarizadeh, A., Mashreghi, M., Mirhadi, E., Mehrabian, A., Shargh, V. H., Badiee, A., Alavizadeh, S. H., Arabi, L., Kamali, H., & Jaafari, M. R. (2023) · Journal of Liposome Research · doi:10.1080/08982104.2023.2247079 · Cited by 13
“…50 – 200 nm have the highest tendency to long circulation and enhanced accumulation in tumors via the enhanced permeability and retention (EPR) effect while show a reduced uptake profile by the liver and spleen macrophages and avoid the renal clearance (Subhan et al. 2021, Matsumura & Maeda 1986).”
BackgroundMesoporous silica nanoparticles: a versatile carrier platform in lung cancer management
Dhingra, S., Goyal, S., Thirumal, D., Sharma, P. M., Kaur, G., & Mittal, N. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2348438 · Cited by 13
Shaikh, S., Chary, P. S., & Mehra, N. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01527 · Cited by 13
Seyam, S., Alallam, B., Fadzilah, N. H., & Kadir, E. A. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114036 · Cited by 16
Bassiony, H., El-Ghor, A. A., Salaheldin, T. A., Sabet, S., & Mohamed, M. M. (2022) · Biological Trace Element Research · doi:10.1007/s12011-022-03102-z · Cited by 13
“The present results suggest that MNPs could successfully be uptaken by tumor tissues and more accumulated in tumor after IT injection, as a result of enhanced permeability and retention (EPR) in tumor tissue and the perforated leaky tumor-associated blood vessels which allow molecules to accumulate passively in the tu…”
BackgroundParveen, F., Madni, A., Torchilin, V. P., Rehman, M., Jamshaid, T., Filipczak, N., Rai, N., Khan, M. M., & Khan, M. I. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s359664 · Cited by 13
“The narrow distribution and nanometric size of carriers are critical parameters for achieving enhanced permeability and retention (EPR) effect-based targeting during cancer treatments.(6) The dynamic light scattering technique and zeta sizer software was utilized to determine the intensity of scattered light that demo…”
BackgroundMethodSelf-citationRetractedAl‐Salih, M. Y. A., Pouresmaeil, V., Davoodi‐Dehaghani, F., Haghighi, H. N., & Tabrizi, M. H. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301122 · Cited by 13
Xiao, B., Adjei‐Sowah, E., & Benoit, D. S. W. (2023) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2023.102727 · Cited by 15
Dmochowska, N., Milanova, V., Mukkamala, R., Chow, S. K. K., Pham, N. T., Srinivasarao, M., Ebert, L. M., Stait‐Gardner, T., Le, H. V., Shetty, A., et al. (2023) · Small · doi:10.1002/smll.202204956 · Cited by 12
The Emerging Role of Cell Membrane-coated Nanomaterials in Cancer Therapy
Bhattacharya, S., & Beninger, P. R. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128295414240221063434 · Cited by 12
Raj, A., Sarath Chandran, C., Dua, K., Kamath, V., & Alex, A. T. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176914 · Cited by 12
FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development
Kwon, W. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e320 · Cited by 13
“44 Pharmacokinetic analysis of erdafitinib demonstrated a direct correlation between the administered dose and both the peak plasma concentration and the area under the curve for serum concentration over time.”
BackgroundUnravelling the potential role of polyethyleneimine (PEI)-based nanosystems in skin cancer therapy
Kumar, A., Das, S. S., Tambe, S. M., Kaundal, B., Sarraf, S. K., & Kesari, K. K. (2024) · Materials Advances · doi:10.1039/d4ma00802b · Cited by 13
In vitro evaluation of lipidic nanocarriers for mebendazole delivery to improve anticancer activity
Tamma, M. A., Nsairat, H., El‐Tanani, M., & Madi, R. (2024) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2024.2428405 · Cited by 12
“…surface features of drug particles. subhan et al. reported that nanoparticles ranging in size from 40 to 400 nm are ideal for ensuring lengthy circulation duration and increased accumulation in tumors with limited renal clearance. shape and morphology are also key factors in passive targeting [40].”
Navigating liver cancer: Precision targeting for enhanced treatment outcomes
Jain, A., Mishra, A. K., Hurkat, P., Shilpi, S., Mody, N., & Jain, S. K. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01780-x · Cited by 12
“Therefore, quantifying the EPR effect is essential [86].”
Kim, K. (2025) · Gels · doi:10.3390/gels11030170 · Cited by 15
Chennamsetty, S., Keerikkadu, M., Shetty, A., Bangera, P. D., Tippavajhala, V. K., & Rathnanand, M. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126400 · Cited by 15
Enzyme‐Activatable Polypeptide for Plasma Membrane Disruption and Antitumor Immunity Elicitation
Liu, J., Li, R. S., Zhang, L., Wang, J., Dong, Q., Xu, Z., Kang, Y., & Xue, P. (2023) · Small · doi:10.1002/smll.202206912 · Cited by 13
Panda, S. P., & Singh, V. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03402-y · Cited by 14
Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy
Guo, L., Yang, J., Wang, H., & Yi, Y. (2023) · Molecules · doi:10.3390/molecules28237750 · Cited by 12
“The unsat-isfied performances of nanomedicines in the clinic are possibly due to the unspecific delivery and the highly heterogeneous EPR effect in patients [142–145].”
BackgroundSOLID LIPID NANOPARTICLES: A REVIEW ON DIFFERENT TECHNIQUES AND APPROACHES TO TREAT BREAST CANCER
Gajbhiye, S. A., & Patil, M. P. (2023) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2023v15i2.46970 · Cited by 12
Shimoyama, S., Okada, K., Kimura, T., Morohashi, Y., Nakayama, S., Kemmochi, S., Makita-Suzuki, K., Matulonis, U. A., & Mori, M. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0099 · Cited by 11
“The leaky vasculature and impaired lymphatic drainage in the tumor microenvironment (TME) is thought to ,amechanismknownastheenhancedpermeabilityand retention (EPR) effect (18).”
Manhas, P., Cokca, C., Sharma, R. K., Peneva, K., Wangoo, N., Sharma, D., & Sharma, R. K. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129242 · Cited by 11
Shoaib, A., Javed, S., Tabish, M., Khan, M. E., Zaki, M., Alqahtani, S. S., Sultan, M. H., Ahsan, W., & Afzal, M. F. (2024) · Nanotechnology Reviews · doi:10.1515/ntrev-2024-0023 · Cited by 14
Nano-based drug delivery systems in hepatocellular carcinoma
Abtahi, M. S., Fotouhi, A., Rezaei, N., Akalın, H., Özkul, Y., Hossein‐Khannazer, N., & Vosough, M. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2365937 · Cited by 12
Grigoriev, V., Korzun, T., Moses, A. S., Jozić, A., Zhu, X., Kim, J., Newton, S., Eygeris, Y., Diba, P., Sattler, A. L., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c06930 · Cited by 11
Nano-fluorescence imaging: advancing lymphatic disease diagnosis and monitoring
Han, C. Y., Choi, S., Chi, S., Hong, J. H., Cho, Y., & Kim, J. (2024) · Nano Convergence · doi:10.1186/s40580-024-00462-1 · Cited by 12
“…DepoDur® (in 2004), Marqibo® (in 2012), LipoDox® (in 2013), Onivyde® (in 2014), CYXEOS® (in 2017), Shingrix® (in 2017), Arykayce® (in 2018), ONPATTRO® (in 2018), COMIRNATY™ (in 2021), and SPIKEVAX™ (in 2022)—to treat various diseases, underscoring the clinical relevance of liposomes [42, 128–130].”
Tiwari, A., Tiwari, V., Sharma, A., Marrisetti, A. L., Kumar, M., Rochani, A., Kaushik, D. K., Mittal, V., Renuka Jyothi, S., Ali, H., et al. (2024) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2024-0338 · Cited by 13
Thi, P. L., Nguyen, D. T., Nguyen, T. P., Hoang, A. Q., Hoang, K. H., Nguyen, H. D., Trân, N. Q., Nguyen, T. L., Nhi, T. T. Y., Hong, J., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.141160 · Cited by 11
Combating chemoresistance: Current approaches & nanocarrier mediated targeted delivery
Shaw, S., Pore, S. K., Liu, D., Kumeria, T., Nayak, R., & Bose, S. K. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189261 · Cited by 12
Razavi, M. S., Ahmadi, F., Ebrahimnejad, P., Akbarzadeh, A., Farokhrou, M., & Nokhodchi, A. (2024) · Pharmaceutical Sciences · doi:10.34172/ps.2023.27 · Cited by 17
“16,17 In herbal medicine, nanotechnology has been employed to develop nanostructured formulations, which harness the potent active compounds present in various parts of medicinal plants, such as roots, rhizomes, and stem bark.”
BackgroundOptimization of atorvastatin and quercetin-loaded solid lipid nanoparticles using Box-Behnken design
Lalchandani, D. S., Chenkual, L., Sonpasare, K., Rajdev, B., Naidu, V. G. M., Chella, N., & Porwal, P. K. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2364585 · Cited by 12
Combinatory Immunotherapy for Glioblastoma Treatment
Ijaz, M., Hasan, I., Jiang, Z., Ullah, Z., Aslam, B., Khurshid, M., Sun, Y., & Guo, B. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400217 · Cited by 12
Li, Y., Liu, P., Zhang, B., Chen, J., & Yan, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02014-3 · Cited by 11
“…EPR effect and improvement of the therapeutic effects of nanotherapeutics by using EPR enhancers is a vital approach to developing cancer therapy [62]. b. Combination therapies: Integrating the EPR effect with other treatment modalities, such as immunotherapy or radiotherapy, to improve overall…”
Lee, C. E., Noh, K. M., Kim, S., Hong, J.-Y., & Kim, K. (2025) · Biomaterials Research · doi:10.34133/bmr.0170 · Cited by 10
Jayalakshmi, C. S., Haider, M. A., & Sanpui, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143898 · Cited by 10
Parvin, N., Aslam, M., Alam, M. N., & Mandal, T. K. (2025) · Micromachines · doi:10.3390/mi16121371 · Cited by 10
“These studies reveal whether nanoparticles achieve sufficient tumor accumulation via passive (EPR effect) or active targeting, and whether undesired organ deposition occurs in the liver, spleen, or kidneys [121].”
Hamzah, H. M. (2026) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2025.15403 · Cited by 11
Day, S., Pérez, B., Díaz, D. G., Mariño‐Ocampo, N., Zúñiga‐Núñez, D., Faúndez, M., Soto‐Arriaza, M., Pizarro, N., Heyne, B., & Fuentealba, D. (2023) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2023.115388 · Cited by 10
Sun, Y., Wen, S., Shi, S., & Chen, Y. (2024) · IEEE Transactions on Molecular Biological and Multi-Scale Communications · doi:10.1109/tmbmc.2024.3361251 · Cited by 11
“However, the targeting efficiency of this purely passive delivery approach is generally less than 2% [17], [18], [19].”
BackgroundNanocarrier design for pathogen-inspired innate immune agonist delivery
Kane, G. I., Brassil, M. L., Diaz-Infante, M. B., & Atukorale, P. U. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.07.007 · Cited by 11
Synthesis and applications of metal organic frameworks in photodynamic therapy
Songca, S. P. (2024) · Journal of Photochemistry and Photobiology · doi:10.1016/j.jpap.2024.100245 · Cited by 9
Interrogation of the tumor microenvironment by nanoparticles
Panja, P., Manne, U., Awasthi, V., Bhattacharya, R., & Mukherjee, P. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217454 · Cited by 10
RETRACTED: Transferrin-guided liposomal nanocarriers: A strategy for targeted cancer treatment
Saeed, M., Altamash, M., Almoyad, M. A. A., Wahab, S., Gupta, G., Goh, K. W., & Kesharwani, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145377 · Cited by 9
RetractedNanomedicine approaches for treatment of hematologic and oncologic malignancies
Nteli, P., Bajwa, D. E., Politakis, D., Μichalopoulos, C., Kefala-Narin, A., EFSTATHOPOULOS, E. P., & Gazouli, M. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i7.553 · Cited by 9
Lerchbammer-Kreith, Y., Hejl, M., Vician, P., Jakupec, M. A., Berger, W., Galanski, M. S., & Keppler, B. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051515 · Cited by 10
“Therefore, the development of drug delivery molecules in the nanometer range is of special interest [12,13].”
BackgroundOcaña-Arakachi, K. D., Martínez-Herculano, J., Jurado, R., Munive, M. L., & García‐López, P. (2023) · Pharmaceuticals · doi:10.3390/ph16101337 · Cited by 9
“Due to the difference in vascular structure between tumor tissue and normal tissue, and to the nanoparticle size, the EPR effect favors a greater accumulation of liposomes in tumor cells [36].”
BackgroundRecent advancements in nanomedicine as a revolutionary approach to treating multiple myeloma
Shafiei, F. S., & Abroun, S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122989 · Cited by 9
Wang, Y., Tian, J., Han, Y., Liu, Y., Chen, S., & Guo, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.978603 · Cited by 11
“With the passage of time, due to the EPR effect and the absence of lymphatic drainage, the concentration of drugs gradually increases in tumours, eventually reaching levels that are many times greater than those in plasma (11).”
BackgroundThankachan, D., Anbazhagan, R., Krishnamoorthi, R., Tsai, H., Gebrie, H. T., Darge, H. F., Lu, C., & Chen, J.-K. (2022) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2022.104503 · Cited by 9
Sun, Y., Wu, Q., Fu, Q., Cong, H., Shen, Y., Yu, B., & Hu, H. (2023) · Talanta · doi:10.1016/j.talanta.2023.125242 · Cited by 10
Liu, Y., Yu, S., Chen, Y., Hú, Z., Fan, L., & Liang, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1376955 · Cited by 10
“Even though the ERP effect allows nanodrugs to pass through broken blood vessels, lacking targeting decoration limits their active accumulation and deep penetration in tumor tissues (Subhan et al., 2021).”
Pandey, S. S., Joshi, S., Tripathi, P., Gupta, A. R., & Yadav, J. S. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167956 · Cited by 8
Computation-aided design of rod-shaped nanoparticles for tumoral targeting
Lee, J., Zhang, W., Nguyen, T. D., Zhou, L., Amengual, J., Zhai, J., Cote, T., Landolina, M., Ahmadi, E., Sands, I., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114169 · Cited by 9
“This is likely due to their rod shape, as Rod JBNp have improved the enhanced permeability and retention (EPR) effect and infiltration into the tumors [19,20].”
Metal oxide nanoparticles: emerging stars in biomedical application
Shanumuganandam, P., & Thangavelu, S. (2025) · BioMetals · doi:10.1007/s10534-025-00749-8 · Cited by 8
“When considering active targeting, it’s essential to recognize that this approach primarily enhances drug uptake and cell recognition, with little to no benefit in overall drug accumulation within tumors (Hladky and Barrand 2018; Subhan et al. 2021; Bakrania et al. 2021).”
Applications of Nanobiotechnology in Medicine
Aebisher, D., Dynarowicz, K., Rudy, I., Rogóż, K., Bartusik‐Aebisher, D., & Kawczyk‐Krupka, A. (2026) · Life · doi:10.3390/life16020302 · Cited by 8
“As a result, overreliance on the EPR effect has been recognized as one of the factors contributing to the gap between promising preclinical nanomedicine results and modest clinical outcomes [28].”
Dwivedi, J., Wal, A., Seemab, M., Singh, A., Wal, P., Tiwari, M., Sharma, K. K., & Gasmi, A. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2698781 · Cited by 10
Hydroxyapatite Nanocrystals Integrated into Mesoporous Silica for Sustained Delivery of Doxorubicin
Bessa, I. A. A., Cruz, J. V. R., Silva, A. F. M. D., D'Amato, D. L., Ligiéro, C. B. P., Gomes-da-Silva, N. C., Archanjo, B. S., Pinto, L. F. R., Santos‐Oliveira, R., Rossi, A. M., et al. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c04519 · Cited by 8
Kang, H. J., Hoang, Q. T., Min, J. S., Son, M. S., Tram, L. T. H., Kim, B. C., Song, Y., & Shim, M. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063474 · Cited by 8
Glass, K., Fines, C. B., Coulter, P., Jena, L., McCarthy, H. O., & Buckley, N. E. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00299 · Cited by 8
Gómez-González, E., Caro, C., Nuñez, N. O., González‐Mancebo, D., Urbano‐Gámez, J. D., García‐Martín, M. L., & Ocaña, M. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb01157k · Cited by 9
Immune Cells as Trojan Horses for Cancer Nanotherapy
Hermosillo‐Abundis, C., Flood-Garibay, J. A., Ayala‐Nunez, V., & Mendéz-Rojas, M. A. (2024) · ACS Materials Letters · doi:10.1021/acsmaterialslett.4c01523 · Cited by 8
Metadata
- Authors
- Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-18
- Volume
- 11
- Issue
- 6
- Pages
- 571
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8234032
- OpenAlex
- W3174294541
- Semantic Scholar
- 0e274cc5538c8ce64b42706c752e9cd357ce4ede
- Cited by
- 623
- References
- 172
- Citations by year
- 2026: 116 · 2025: 167 · 2024: 148 · 2023: 106 · 2022: 82 · 2021: 4
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor targeting, cancer nanomedicine, nanotherapeutics, tumor selectivity, intravenous drug delivery, tumor microenvironment, lymphatic drainage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.